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material and provided the activities. A feedback was requested from participants after 
each training session; specific questions were included in the annual general survey 
for Partners. Results: Partners have been offered three face-to-face courses and sev-
eral webinars which reached 90 people from 27 agencies and 25 countries. e-learning 
material (webcasts or recorded training sessions) were also created. All participants 
were satisfied or very satisfied, 70 % indicated having changed their practice follow-
ing the training event. Stakeholders have been offered three face-to-face courses, 
which reached 70 participants (mostly patient organisations and manufacturers). All 
participants were satisfied of very satisfied ConClusions: EUnetHTA has succeeded 
in establishing a training program. Because EUnetHTA is a transnational network, use 
of e-learning should be extended so that more Partners will be able to increase their 
knowledge on EUnetHTA tools and methods in order to efficiently produce joint HTA 
information. Stakeholders also benefited from the training program to get a better 
comprehension of both HTA and EUnetHTA tools and methods. However, cost of 
pursuing this activity will need to be further assessed.
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objeCtives: It has been argued that the selection criteria of comparator treat-
ments suggested by the cost-effectiveness (CE) guideline in Korea are too restrictive 
and unrealistic for a valid CE assessment. The use of inappropriate comparators 
could result in an incorrect value assessment of a new drug leading to invalid reim-
bursement decisions. Thus, we conducted a study to investigate practical gaps in 
comparator selection to improve the validity of CE analysis. Methods: We per-
formed an online survey among all staff of the 35 member companies of the Korea 
Research-based Pharmaceutical Industry Association (KRPIA) whose workplace 
duty is related to CE evidence generation and/or submission to the government. 
In the questionnaire, we presented a hypothetical situation based on each of the 
practical gaps identified by the focus group interviews (FGI) and asked the respond-
ents whether they had experienced it. A total of 50 out of 90 people included in 
the survey responded to the survey between November 11 and 26, 2014, yielding a 
response rate of 53.8%. Results: Among the eight gaps presented in the survey, 
the highest proportion of respondents experienced “difficulty in obtaining reliable 
market share data needed to select a comparator” (94%), followed by “drug widely 
used for a long time selected as comparator for new drug because it was recog-
nized as a standard treatment” (88%), “uncertainties in indirect comparison” (78%), 
“therapeutically nonequivalent drugs as comparators” (72%), and “price of new drug 
compared with price of generic product rather than initial price of original prod-
uct” (70%) . The lowest number of respondents experienced “inclusion of off-label 
drugs as comparators” (36%). ConClusions: We expect our investigation results 
to improve the quality of CE guidelines for valid selection of comparators in South 
Korea as well as other countries, and, consequently, help assess the true value of 
pharmaceutical interventions.
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objeCtives: Health Technology Assessment (HTA) is an integral part of modern 
health care system of developed countries. It is carried out to study decision-making 
and policy-making in health care based on objective information and evidence 
base. In Ukraine HTA reports are the one of the sources of evidence-based medicine 
which are used to develop medical and technological documents on standardiza-
tion of medical care. Methods: The introduction of HTA in Ukraine requires its 
own methodology. For the development of this methodology a systematic review 
of the literature for HTA was performed. The sources were analyzed for the pos-
sibility of adaptation in Ukraine. Results: On the basis of the detected data, and 
based on the knowledge gained from ISPOR distance learning and short courses 
an instruction was designed to conduct analytical work with sources of scientific 
information on the possible inclusion of drugs to medical and technological docu-
ments. Several types of analytical work were included in the instruction: - Analytical 
work with sources of scientific information on the possible inclusion of drugs to 
medical and technological documents; - Systematic search of information sources; 
- Construction of tables of evidence; - Transferal of ready HTA reports to the national 
health system; - Conducting of HTA reports. ConClusions: Introduction of the 
system of medical technology assessment is a multilevel process that requires crea-
tion of appropriate scientific and technical base, training of qualified specialists and 
amendment of relevant regulations. An important component of this process is the 
exchange of experience and knowledge in this area through access to networks such 
as INAHTA, HTAi, EUnetHTA, and others.
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objeCtives: Following a review into access to new medicines in NHS Scotland, SMC 
was directed to improve transparency and increase access to new medicines used 
at the end of life and for rare conditions.This paper outlines the experience with 
introducing these changes in the first year. Methods: SMC advises NHS Scotland 
on the clinical and cost-effectiveness of all new medicines. In January 2014, we 
began to implement a number of recommendations to improve public transparency 
and increase access to new medicines used at the end of life and for rare condi-
tions. Changes introduced include: holding all SMC meetings in public to increase 
understanding of how the committee works; introducing a more flexible approach 
environment allows us to identify four ideal-types of HB-HTA units: the independent 
group, the integrated-specialized units, the standalone units and the integrated-
essential units. ConClusions: Our results provide useful information on how 
different organizations face the challenges of HB-HTA. The findings and can be 
beneficial for policy-makers and professionals implementing HB-HTA and may give 
an overview on the next steps that the HB-HTA units could follow to further improve 
their current ways of working.
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objeCtives: In anticipation of official requirements of economic evidence by 
the Japanese government from April 2016, the present study aims to assess past 
experience and current capability of the industry to submit the economic evi-
dence to the government, and to identify what the industry perceives for their 
capacity building. Methods: A self-administered questionnaire was distributed 
to a person who was in charge of economic evidence or those most relevant (e.g., 
those in charge of market access), within every 72 member companies of Japanese 
Pharmaceutical Manufacturers Association, in March 2015. Semi-structured inter-
views were conducted with three HEOR experts of the pharamceutical industry to 
assess the consistency of the survey results. Results: 18 companies responded 
to the survey with the response rate of 25%. 12 companies had no experience 
submitting economic evidence to the government, mostly because of no merit for 
the industry. 8 companies had health economics experts. 14 companies answered 
they have great concern about lack of clarity and transparency in the way how the 
government would use economic evidence submitted. Most of the respondents 
were concerned about patient access, additional costs, human resource, and data 
availability. They expressed their unfavorable response to the new policy in the 
context of creating new business opportunities, and had a sense of resistance 
towards the use of ICER threshold for evaluation. The interviewee’s responses 
were consistent with the survey results. ConClusions: Our survey observed 
that industry’s concerns regarding the upcoming policy are high and their pre-
paredness is limited. For the industry to respond appropriately to the new policy, 
further improvement in transparency of requirements will be a key, in addition 
to capacity building in the industry.
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objeCtives: There is growing interest, activity, and funding to increase the level 
of HTA collaboration in Europe, with the aim of reducing duplication, increasing 
efficiency, and improving evidence-based decision making. The expectation for 
the next 3 years of EU HTA collaboration is that learnings from early pilot activity 
will transform the process into a scalable, sustainable process by 2020. Methods: 
EUnetHTA has undertaken 12 pilots evaluating the ability to undertake collabora-
tive Relative Effectiveness Assessments (REA). Johnson & Johnson reviewed its 
participation in 4 of the pilots: two pharmaceuticals, two medical devices. One of 
each was alongside regulatory approval and one of each post launch. Results: J&J 
contributed to a third of EUnetHTA pilots: 2 of 6 drugs; 2 of 6 devices. Experience 
identified that the issues required to achieve a sustainable relevant platform differ 
between pharmaceuticals and medical devices. For Pharmaceutical developers, 
the biggest challenges appear to be practical process issues, such as the tim-
ing of the REA report for inclusion in local processes, and policy issues related 
to uptake of reports within member states. For medical device developers, the 
main challenges appear how to predict which technology is likely to be selected 
for collaborative REA, what decision is likely to be informed within EU member 
states, and when in the product lifecycle the review will occur. ConClusions: 
For collaborative REA to move from pilot ‘proof of concept’ to being a sustainable 
platform, as intended by the European Commission by 2020, the differing issues 
between various healthcare sectors need to be recognized and addressed sepa-
rately. Stakeholders engaged in developing technologies, as well as those who will 
use the outputs within member states need to be engaged to design and align on 
processes capable of delivering the reductions in duplication and providing the 
efficiency gains proposed by policy makers.
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objeCtives: Provide training activities to facilitate uptake and ensure the optimal 
use of the EUnetHTA tools and methods. In the last decade, EUnetHTA (the European 
network for Health Technology Assessment), has developed several tools and methods 
to facilitate joint production of HTAs by Partners. In order to favour their imple-
mentation and practical use, providing training is required. Additionally, EUnetHTA 
Stakeholders expressed an interested in trainings about the same topics. Methods: 
Partners and Stakeholders were surveyed to identify their training needs, collect 
their training format preference and identify which tool and methods to prioritize. A 
training program including both face-to-face and online activities was set up. Training 
opportunities were advertised using news items on the intranet and on the public site, 
pamphlets, newsletters and direct e-mail. Tool and method developers created the 
